This review examines the Mazara product marketed for erectile dysfunction, its advertised ingredients, clinical evidence, safety information and purchase terms. A contradictory serving count in the product imagery also needs clarification before its value can be judged confidently.

This is a review of published information. No product sample was taken or independently laboratory tested, and the article does not claim personal treatment results.

Product details

The information below comes from the sales page and its Supplement Facts image. It describes the seller’s presentation, not independently verified contents.

The serving is three softgels. The advertising should not be read as 600 mg in each softgel. Its declared amount works out to 200 mg per softgel, assuming the three contain equal amounts.

The gelatin source is not specified in the displayed ingredient list. Anyone with dietary or religious restrictions should ask the supplier for confirmation.

The serving count needs correcting

The product image contains an inconsistency that affects both expectations and cost. It shows a pouch containing 120 softgels and a serving size of three, but the facts panel also states that the container holds 120 servings.

Those figures cannot all describe the same pack. A pack of 120 softgels taken three at a time supplies 40 daily servings. A pack with 120 such servings would need 360 softgels.

This could be an artwork error. It does not, by itself, prove that the product is defective. Nevertheless, accurate dose and quantity information are basic requirements for an informed purchase. Ask for a photograph of the actual current packaging and written confirmation of the number of softgels supplied.

What the erectile dysfunction research shows

The most relevant study behind the sales pitch was published in 2013. It involved 45 men with type 2 diabetes and erectile dysfunction, comparing alpha-lipoic acid treatment with transdermal testosterone over 12 weeks. Erectile-function questionnaire scores improved in both groups.

Several limitations affect how that finding should be interpreted:

• It was a small, open-label comparative study. Participants knew which treatment they received.
• The alpha-lipoic acid regimen began with 600 mg delivered parenterally, meaning by injection rather than by mouth, for seven days, followed by oral treatment.
• The research concerned men with type 2 diabetes, limiting its relevance to other causes of erectile dysfunction.
• It did not test Mazara’s product or establish a benefit specific to its isolated R-form formulation.

Our interpretation is that this is preliminary evidence worth investigating, but it does not validate the advertised supplement. A shared milligram number does not make an oral supplement equivalent to a different clinical treatment regimen. Read the original study abstract.

A separate 2022 trial involved 123 men with type 2 diabetes and erectile dysfunction. It studied a supplement combining alpha-lipoic acid with other ingredients, including grape and ginkgo extracts, with and without the prescription medicine avanafil.

The combination with avanafil produced better erectile-function scores than avanafil alone. However, a result from a multi-ingredient formula cannot identify how much benefit came from alpha-lipoic acid, or establish that Mazara would produce the same effect. Read the 2022 trial.

We did not locate a published clinical trial of Mazara’s finished product in the material reviewed.

What the R form and stabilisation mean

R-alpha-lipoic acid is the naturally occurring form of alpha-lipoic acid. Conventional racemic alpha-lipoic acid contains both R and S forms.

Formulation can affect stability and absorption. A small pharmacokinetic study in 12 healthy adults examined sodium R-lipoate and found favourable absorption characteristics. However, it measured how the compound appeared in the blood. It did not demonstrate improved erections or test Mazara’s softgels. Read the pharmacokinetic study.

The Mazara facts image names R-alpha-lipoic acid but does not identify a stabilising salt or provide stability data. We therefore cannot confirm the specific basis for the product’s stabilisation claim.

Our view is that the R-form description is a formulation detail, not sufficient evidence of superior clinical results. A useful supporting document would identify the exact ingredient, its purity and how potency is maintained through the expiry date. The inclusion of coconut oil also does not, by itself, establish better treatment outcomes.

Does the nerve health evidence strengthen the case

Alpha-lipoic acid has been studied more extensively for diabetic peripheral neuropathy than for erectile dysfunction.

The 2006 SYDNEY 2 trial, involving 181 participants, found that oral alpha-lipoic acid improved neuropathy symptoms over five weeks. This supports a possible short-term benefit for some people, but the trial did not test erectile function or Mazara’s product. Read SYDNEY 2.

Longer-term findings are less encouraging. A 2024 Cochrane review of three studies analysing 816 adults concluded that alpha-lipoic acid probably provides little or no improvement over placebo in neuropathy symptoms after six months. The review considered treatment lasting at least six months, so it addresses a different question from short trials. Read the Cochrane review.

These findings do not justify assuming that a supplement permanently repairs nerves or that a benefit for foot symptoms would necessarily improve erections.

Marketing claims that deserve caution

The ED sales page presents a timetable for returning sexual function and makes claims about eliminating performance anxiety and completing vascular repair. It also displays percentages suggesting that many users regained spontaneous erections or stopped ED medicines.

We could not verify a published survey method, sample description or clinical dataset supporting those percentages on the reviewed page. They should not be interpreted as an individual buyer’s probability of success.

There is also a testimonial referring to NAD+, a different substance. Its presence reduces the usefulness of that testimonial as evidence about R-alpha-lipoic acid. It does not establish whether any particular customer account is authentic.

A product can have a plausible biological explanation without having demonstrated the promised outcome. Marketing about nerves, nitric oxide and circulation needs to be supported by trials of the relevant formulation and patient group.

Erectile dysfunction has multiple possible causes, including vascular disease, hormonal problems, medication effects and psychological factors. A sales explanation centred on nerve signalling cannot establish the cause in an individual reader. Healthdirect explains the causes and assessment of ED.

Side effects and medication considerations

Alpha-lipoic acid is often tolerated, but it is not free of adverse effects. The US National Center for Complementary and Integrative Health lists headache, heartburn, nausea and vomiting among its common side effects. Read the NCCIH safety information.

Blood glucose deserves particular attention. Alpha-lipoic acid may add to the effects of glucose-lowering medicines. People taking diabetes medication, or experiencing low glucose readings, should discuss the product and a monitoring plan with their doctor or pharmacist before starting. Do not adjust prescribed medicines in response to a sales testimonial. Read the medication interaction information from Memorial Sloan Kettering.

Health Canada has also identified a rare association between alpha-lipoic acid and insulin autoimmune syndrome, which can cause hypoglycaemia in susceptible people. Its advice is to stop the supplement and consult a healthcare professional if symptoms such as sweating, dizziness or confusion develop. This is an ingredient-related risk, not a finding that Mazara specifically caused these events. Read Health Canada’s safety review.

Product quality and Australian buyers

The marketing imagery includes laboratory-testing, manufacturing and GMP claims. We did not verify a certificate of analysis tied to a current batch, an independent laboratory report or the supporting manufacturing certification.

That is an information gap, rather than proof that no testing takes place. Before buying, ask for a report that identifies the batch, laboratory, ingredient identity, measured potency and contaminant results.

We also could not verify an Australian Register of Therapeutic Goods number from the product materials reviewed. Australian buyers should ask the supplier about the exact product’s regulatory status and confirm any supplied number against the register.

An AUST L number should not be interpreted as proof that the TGA has individually assessed a product’s efficacy. The TGA explains that ordinary listed medicines are not individually evaluated before market entry. Read the TGA’s explanation of listed medicines.

Price and refund terms

The direct page displayed US$34.99 when checked. A separate Shop listing for the ED product displayed A$52 for a one-time purchase, alongside a monthly subscription option. These are observed listing prices, not a confirmed Australian checkout total.

If the pack contains 120 softgels and the daily serving is three, those prices work out to approximately US$0.87 or A$1.30 per day over 40 days, before delivery and any additional charges. This calculation depends on the pack count being correct.

The page linked as the refund policy primarily presented promotional content when reviewed. It repeated a 90-day refund promise but did not clearly resolve practical details such as the return address, postage costs and treatment of opened packs.

Get those terms in writing and check whether checkout is a single purchase or recurring order. We did not place an order or test the refund process. A refund promise provides no evidence of medical effectiveness.

Our purchasing assessment

There are reasonable grounds for continued research into alpha-lipoic acid, and it would be unfair to describe the ingredient as having no scientific basis. Mazara also presents a declared dose and an ingredient list, which are useful starting points.

However, we would not recommend buying this product on the strength of its ED recovery claims. The cited research does not establish the effectiveness of this finished formulation, the quantity information is inconsistent, and important quality and purchasing details remain unverified.

For someone considering alpha-lipoic acid after a clinical discussion, the next step is to obtain a corrected label, batch-specific testing and clear purchase terms. Paying for the R-form description alone is difficult to justify without evidence that the formulation offers a meaningful advantage.

Persistent or new erectile difficulties deserve medical assessment because they can sometimes reveal an underlying health condition. Treatment can include management of contributing conditions, lifestyle changes, counselling and prescribed medicines where appropriate. Healthdirect outlines the available approaches.

This consumer review provides general information and does not replace individual medical advice.